CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← PALISADE BIO, INC. (PALI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

PALISADE BIO, INC. (PALI)

Biological Products, (No Diagnostic Substances) · market cap $284M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-10-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Palisade Bio (PALI) is a clinical-stage biotech with a market cap of ~$342M and a single disclosed lead asset, LB1148, currently in Phase 2 development for postoperative ileus. The company carries $132.6M in cash (roughly 102 months of runway) and generates no revenue, burning approximately $10M in R&D annually.
The catalyst path
  • 2027-10-15 (est.)Phase 2 · PALI-2108imp 7/10
Pipeline
AssetPhaseIndication
LB1148Phase 2Ileus
PALI-2108Phase 2Ulcerative Colitis (UC)
Price & technical context
3-month
-47.9%
6-month
-38.8%
12-month
-45.1%
52-wk range
$1.12–$2.80
vs 50-day MA
-24.3%
vs 200-day MA
-38.5%
Realized vol
88.8%
Max drawdown
-86.2%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for PALI (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.